Biodel Inc. - Product Pipeline Review - 2015

Date: February 28, 2015
Pages: 39
Price:
US$ 1,500.00 US$ 1,200.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B3987FBCCBBEN
Leaflet:

Download PDF Leaflet

Biodel Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Biodel Inc. - Product Pipeline Review - 2015’, provides an overview of the Biodel Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biodel Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of Biodel Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Biodel Inc.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Biodel Inc.’s pipeline products
Reasons to buy
  • Evaluate Biodel Inc.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Biodel Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Biodel Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Biodel Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biodel Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Biodel Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Biodel Inc. Snapshot
Biodel Inc. Overview
Key Information
Key Facts
Biodel Inc. - Research and Development Overview
Key Therapeutic Areas
Biodel Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Biodel Inc. - Pipeline Products Glance
Biodel Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Biodel Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Biodel Inc. - Drug Profiles
BIOD-123
Product Description
Mechanism of Action
R&D Progress
BIOD-531
Product Description
Mechanism of Action
R&D Progress
BIOD-125
Product Description
Mechanism of Action
R&D Progress
BIOD-238
Product Description
Mechanism of Action
R&D Progress
BIOD-250
Product Description
Mechanism of Action
R&D Progress
glucagon
Product Description
Mechanism of Action
R&D Progress
VIAtab
Product Description
Mechanism of Action
R&D Progress
BIOD-530
Product Description
Mechanism of Action
R&D Progress
teriparatide
Product Description
Mechanism of Action
R&D Progress
VIAcal
Product Description
Mechanism of Action
R&D Progress
Biodel Inc. - Pipeline Analysis
Biodel Inc. - Pipeline Products by Target
Biodel Inc. - Pipeline Products by Route of Administration
Biodel Inc. - Pipeline Products by Molecule Type
Biodel Inc. - Pipeline Products by Mechanism of Action
Biodel Inc. - Recent Pipeline Updates
Biodel Inc. - Dormant Projects
Biodel Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
BIOD-105
BIOD-107
Linjeta
Biodel Inc. - Company Statement
Biodel Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Biodel Inc., Key Information
Biodel Inc., Key Facts
Biodel Inc. - Pipeline by Indication, 2015
Biodel Inc. - Pipeline by Stage of Development, 2015
Biodel Inc. - Monotherapy Products in Pipeline, 2015
Biodel Inc. - Phase II, 2015
Biodel Inc. - Phase I, 2015
Biodel Inc. - Preclinical, 2015
Biodel Inc. - Pipeline by Target, 2015
Biodel Inc. - Pipeline by Route of Administration, 2015
Biodel Inc. - Pipeline by Molecule Type, 2015
Biodel Inc. - Pipeline Products by Mechanism of Action, 2015
Biodel Inc. - Recent Pipeline Updates, 2015
Biodel Inc. - Dormant Developmental Projects,2015
Biodel Inc. - Discontinued Pipeline Products, 2015
Biodel Inc., Other Locations
Biodel Inc., Subsidiaries

LIST OF FIGURES

Biodel Inc. - Pipeline by Top 10 Indication, 2015
Biodel Inc. - Pipeline by Stage of Development, 2015
Biodel Inc. - Monotherapy Products in Pipeline, 2015
Biodel Inc. - Pipeline by Top 10 Target, 2015
Biodel Inc. - Pipeline by Top 10 Route of Administration, 2015
Biodel Inc. - Pipeline by Top 10 Molecule Type, 2015
Biodel Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Skip to top


GenSpera, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Aug, 2015 · 27 pages
ImmunoFrontier, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Jun, 2015 · 22 pages
OncoImmune, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Aug, 2015 · 24 pages
Osel Inc. - Product Pipeline Review - 2014 US$ 1,125.00 Jul, 2014 · 20 pages
Quest PharmaTech Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Oct, 2015 · 33 pages

Ask Your Question

Biodel Inc. - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: